News
GRFS
8.69
+3.08%
0.26
Weekly Report: what happened at GRFS last week (1102-1106)?
Weekly Report · 16h ago
Grifols: Plasma, Profits, And Recovery Gathering Momentum
Seeking Alpha · 6d ago
Grifols Q3 Net Profit Rises, Revenue Up 8.4%; On Track To Meet 2026 Guidance
NASDAQ · 6d ago
Grifols S.A. reports Q3 results; says on track to meet its 2026 guidance
Seeking Alpha · 6d ago
Grifols (GRFS) Q3 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Grifols Reports Q3 2026 Revenue and Profit Growth
TipRanks · 11/02 17:24
Grifols Approves €0.15 Interim Dividend Per Share
TipRanks · 11/02 17:23
Grifols Reports Q3 Revenue €2.04B, Up 8.4% YoY; Adj EBITDA €538M; Says On Track To Deliver FY26 Outlook
Benzinga · 11/02 16:44
Weekly Report: what happened at GRFS last week (1026-1030)?
Weekly Report · 11/02 10:20
Here are the major earnings before the open Monday
Seeking Alpha · 11/01 22:00
Grifols Is Maintained at Neutral by JP Morgan
Dow Jones · 10/26 16:04
Grifols Price Target Cut to $9.00/Share From $10.00 by JP Morgan
Dow Jones · 10/26 16:04
Grifols price target lowered to $9 from $10 at JPMorgan
TipRanks · 10/26 11:46
Weekly Report: what happened at GRFS last week (1019-1023)?
Weekly Report · 10/26 10:20
White Falcon Capital Q3 2026 Partner Letter
Seeking Alpha · 10/22 01:15
Weekly Report: what happened at GRFS last week (1012-1016)?
Weekly Report · 10/19 10:20
Weekly Report: what happened at GRFS last week (1005-1009)?
Weekly Report · 10/12 10:26
Weekly Report: what happened at GRFS last week (0928-1002)?
Weekly Report · 10/05 10:25
Grifols Refinanced Its Debt But the Plasma Strategy Hasn't Proven Itself Yet
Barchart · 10/02 16:01
Weekly Report: what happened at GRFS last week (0921-0925)?
Weekly Report · 09/28 10:20
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.